

iBio, Inc.  
Form 424B3  
April 08, 2010

Filed Pursuant to Rule 424(b)(3)  
File Number 333-162424

## **PROSPECTUS SUPPLEMENT NO. 4**

### **Prospectus Supplement No. 4 to Prospectus dated October 21, 2009**

#### **IBIO, INC.**

This Prospectus Supplement No. 4 supplements our Prospectus dated October 21, 2009, as supplemented by Prospectus Supplement No. 1 dated November 16, 2009, Prospectus Supplement No. 2 dated February 17, 2010 and Prospectus Supplement No. 3 dated March 3, 2010. The shares that are the subject of the Prospectus have been registered to permit their resale to the public by the selling stockholders named in the Prospectus. We are not selling any shares of common stock in this offering and therefore will not receive any proceeds from this offering, except upon the exercise of warrants.

Our common stock is quoted on the OTC Bulletin under the symbol IBPM.OB. On April 6, 2010, the closing price of our common stock on the OTC Bulletin Board was \$1.05.

This Prospectus Supplement includes the following attached item:

Current Report on Form 8-K dated April 1, 2010, as filed by us with the Commission on April 6, 2010.

**YOU SHOULD READ THE PROSPECTUS, AS SUPPLEMENTED, INCLUDING THE RISK FACTORS THAT BEGIN ON PAGE 2 OF THE PROSPECTUS.**

**NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

**The date of this Prospectus Supplement is April 6, 2010.**

---

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **April 1, 2010**

**iBio, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-53125**

(Commission File Number)

**26-2797813**

(IRS Employer Identification No.)

**9 Innovation Way, Suite 100**

**Newark, Delaware 19711**

(Address of principal executive offices, including zip Code)

**(302) 355-0650**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Appointment of New Director

Effective April 1, 2010, the Board of Directors (the Board) of iBio, Inc. (the Company) voted to appoint Pamela Bassett, M.D. to serve on the Board. Dr. Bassett will be one of the Board's Class III directors, whose members' terms expire at the Company's annual meeting to be held in late 2011.

There is no arrangement or understanding between Dr. Bassett and any other person, pursuant to which Dr. Bassett is to be appointed as a director. Dr. Bassett is not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

In connection with her appointment, Dr. Bassett was granted a stock option to purchase 60,000 shares of the Company's common stock under the Company's stock incentive plan, which shall vest in three equal annual installments beginning on the first anniversary of Dr. Bassett's service, at an exercise price set at the last trading price on the date of appointment.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

IBIO, INC.

Date: April 6, 2010

By: /s/ Frederick Larcombe

\_\_\_\_\_  
Frederick Larcombe  
Chief Financial Officer